CGTLive’s Weekly Rewind – May 5, 2023

Article

Review top news and interview highlights from the week ending May 5, 2023.

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Liso-cel Approved as Second-Line Treatment in LBCL by European Commission

The decision, which aligns with its indication in the US, was based on efficacy and safety results from Bristol Myers Squibb’s TRANSFORM clinical trial in forms of large B-cell lymphoma.

2. Bart P. Leroy, MD, PhD, on Improving Light Sensitivity, Quality of Life With Luxturna

The head of the Department of Ophthalmology at the Center for Medical Genetics, Ghent University Hospital, discussed the main takeaways of a post-marketing study on the gene therapy.

3. ICER Reports Sickle Cell Gene Therapy Cost Effective at $1.9 Million

The draft report was released shortly after the BLA submission of exa-cel was completed and shortly before submission of lovo-cel.

4. Raphaël Ognar on Developing CIR-NK Cells to Better Target Cancer Cells

The cofounder and chief executive officer of NKILT Therapeutics discussed new preclinical data presented at WOCTC.

5. Liso-cel Meets Primary End Point in Follicular and Mantle Cell Lymphoma Trials

Bristol Myers Squibb noted that in addition to meeting the ORR end point, both trials also met a key secondary CR rate end point.

Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Related Content
© 2025 MJH Life Sciences

All rights reserved.